{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T21:05:38Z","timestamp":1791061538022,"version":"4.1.0"},"reference-count":35,"publisher":"American Society for Microbiology","issue":"5","license":[{"start":{"date-parts":[[2002,5,1]],"date-time":"2002-05-01T00:00:00Z","timestamp":1020211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2002,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    Cidofovir {[(\n                    <jats:italic>S<\/jats:italic>\n                    )-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine] [HPMPC]}-resistant forms of camelpox, cowpox, monkeypox, and vaccinia viruses were developed by prolonged passage in Vero 76 cells in the presence of drug. Eight- to 27-fold-higher concentrations of cidofovir were required to inhibit the resistant viruses than were needed to inhibit the wild-type (WT) viruses. Resistant viruses were characterized by determining their cross-resistance to other antiviral compounds, examining their different replication abilities in two cell lines, studying the biochemical basis of their drug resistance, and assessing the degrees of their virulence in mice. These viruses were cross resistant to cyclic HPMPC and, with the exception of vaccinia virus, to (\n                    <jats:italic>S<\/jats:italic>\n                    )-1-(3-hydroxy-2-phosphonylmethoxypropyl)adenine. Three of the four resistant cowpox and monkeypox viruses exhibited reduced abilities to infect and replicate in 3T3 cells compared to their abilities in Vero 76 cells. Compared to the WT virus polymers the resistant cowpox virus DNA polymerase was 8.5-fold less sensitive to inhibition by cidofovir diphosphate, the active form of the drug. Intracellular phosphorylation of [\n                    <jats:sup>3<\/jats:sup>\n                    H]cidofovir was not stimulated or inhibited by infection with resistant cowpox virus. In intranasally infected BALB\/c mice, WT cowpox virus was 80-fold more virulent than the resistant virus. Cidofovir treatment (100 mg\/kg of body weight, given one time only as early as 5 min after virus challenge) of a resistant cowpox virus infection could not protect mice from mortality. However, the drug prevented mortality in 80 to 100% of the mice treated with a single 100-mg\/kg dose at 1, 2, 3, or 4 days after WT virus challenge. By application of these results to human orthopoxvirus infections, it is anticipated that resistant viruses may be untreatable with cidofovir but their virulence may be attenuated. Studies will need to be conducted with cidofovir-resistant monkeypox virus in monkeys to further support these hypotheses.\n                  <\/jats:p>","DOI":"10.1128\/aac.46.5.1329-1335.2002","type":"journal-article","created":{"date-parts":[[2002,7,27]],"date-time":"2002-07-27T06:09:01Z","timestamp":1027750141000},"page":"1329-1335","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":131,"title":["Characterization of Wild-Type and Cidofovir-Resistant Strains of Camelpox, Cowpox, Monkeypox, and Vaccinia Viruses"],"prefix":"10.1128","volume":"46","author":[{"given":"Donald F.","family":"Smee","sequence":"first","affiliation":[{"name":"Institute for Antiviral Research, Utah State University, Logan, Utah 84322-5600"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert W.","family":"Sidwell","sequence":"additional","affiliation":[{"name":"Institute for Antiviral Research, Utah State University, Logan, Utah 84322-5600"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debbie","family":"Kefauver","sequence":"additional","affiliation":[{"name":"Virology Division, U.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland 21702-5011"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Bray","sequence":"additional","affiliation":[{"name":"Virology Division, U.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland 21702-5011"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W.","family":"Huggins","sequence":"additional","affiliation":[{"name":"Virology Division, U.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland 21702-5011"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/0022-2836(70)90190-7","volume":"50","year":"1970","unstructured":"Altman, S., and L. S. Lerman. 1970. Kinetics and intermediates in the intracellular synthesis of bacteriophage T4 deoxyribonucleic acid. J. Mol. Biol.50:235-261.","journal-title":"J. Mol. Biol."},{"key":"e_1_3_2_3_2","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1177\/095632029700800509","volume":"8","year":"1997","unstructured":"Andrei, G., R. Snoeck, and E. De Clercq. 1997. Differential susceptibility of several drug-resistant strains of herpes simplex virus type 2 to various antiviral compounds. Antivir. Chem. Chemother.8:457-461.","journal-title":"Antivir. Chem. Chemother."},{"key":"e_1_3_2_4_2","first-page":"162","volume":"23","year":"1991","unstructured":"Biron, K. K. 1991. Ganciclovir-resistant human cytomegalovirus clinical isolates; resistance mechanisms and in vitro susceptibility to antiviral agents. Transplant. Proc.23:162-167.","journal-title":"Transplant. Proc."},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.10.2387"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1086\/315190"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199808203390811"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(73)90196-2"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(82)90122-X"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.33.2.185"},{"key":"e_1_3_2_11_2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/0166-3542(83)90011-6","volume":"3","year":"1983","unstructured":"De Clercq, E., and J. A. Montgomery. 1983. Broad-spectrum antiviral activity of the carbocyclic analog of 3-deazaadenosine. Antivir. Res.3:17-24.","journal-title":"Antivir. Res."},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","first-page":"599","DOI":"10.2174\/092986730607220401123801","volume":"6","year":"1999","unstructured":"Franchetti, P., and M. Grifantini. 1999. Nucleoside and non-nucleoside IMP dehydrogenase inhibitors as antitumor and antiviral agents. Curr. Med. Chem.6:599-614.","journal-title":"Curr. Med. Chem."},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1093\/oxfordjournals.aje.a121340","volume":"94","year":"1971","unstructured":"Heiner, G. G., N. Fatima, P. K. Russell, A. T. Haase, N. Ahmad, N. Mohammed, D. B. Thomas, T. M. Mack, M. M. Khan, G. L. Knatterud, R. L. Anthony, and F. R. McCrumb, Jr. 1971. Field trials of methisazone as a prophylactic agent against smallpox. Am. J. Epidemiol.94:435-449.","journal-title":"Am. J. Epidemiol."},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.bmb.a011720"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.9.2240"},{"key":"e_1_3_2_16_2","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1086\/515534","volume":"25","year":"1997","unstructured":"Kesson, A. M., J. K. Ferguson, W. D. Rawlinson, and A. L. Cunningham. 1997. Progressive vaccinia treated with ribavirin and vaccinia immune globulin. Clin. Infect. Dis.25:911-914.","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.66.12.7146-7152.1992"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1997.03890440061010"},{"key":"e_1_3_2_19_2","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1128\/jvi.43.2.673-678.1982","volume":"43","unstructured":"Moss, B., and N. Cooper. Genetic evidence for vaccinia virus-encoded DNA polymerase: isolation of phosphonoacetate-resistant enzyme from the cytoplasm of cells infected with mutant virus. J. Virol.43:673-678.","journal-title":"J. Virol."},{"key":"e_1_3_2_20_2","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1046\/j.1365-2133.1998.02310.x","volume":"139","year":"1998","unstructured":"Munoz-Perez, M. A., A. Rodriguez-Pichardo, F. Camacho, and M. A. Colmenero. 1998. Dermatological findings correlated with CD4 lymphocyte counts in a prospective 3 year study of 1161 patients with human immunodeficiency virus disease predominantly acquired through intravenous drug abuse. Br. J. Dermatol.139:33-39.","journal-title":"Br. J. Dermatol."},{"key":"e_1_3_2_21_2","unstructured":"National Research Council. 1996. Guide for the care and use of laboratory animals rev. ed. National Academy Press Washington D.C."},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.1890410312"},{"key":"e_1_3_2_23_2","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0166-3542(97)00013-2","volume":"35","year":"1997","unstructured":"Okleberry, K. M., R. P. Warren, and D. F. Smee. 1997. Metabolism of ganciclovir and cidofovir in cells infected with drug-resistant and wild-type strains of murine cytomegalovirus. Antivir. Res.35:83-90.","journal-title":"Antivir. Res."},{"key":"e_1_3_2_24_2","first-page":"26","volume":"38","year":"1998","unstructured":"Orent, W. 1998. Escape from Moscow. Sciences (New York) 38:26-31.","journal-title":"Sciences"},{"key":"e_1_3_2_25_2","first-page":"29","volume":"24","year":"1986","unstructured":"Robins, R. K., G. R. Revankar, P. A. McKernan, B. K. Murray, J. J. Kirsi, and J. A. North. 1986. The importance of IMP dehydrogenase inhibition in the broad spectrum antiviral activity of ribavirin and selenazofurin. Adv. Enzyme Regul.24:29-43.","journal-title":"Adv. Enzyme Regul."},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-3542(00)00105-4"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1177\/095632020101200105"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/0166-3542(94)00061-C"},{"key":"e_1_3_2_29_2","first-page":"A52.","volume":"41","year":"1999","unstructured":"Smee, D. F., and J. W. Huggins. 1999. Mode of action of ribavirin against cowpox and monkeypox viruses. Antivir. Res.41:A52.","journal-title":"Antivir. Res."},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.36.9.1837"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.1.19"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.67.7.4323-4336.1993"},{"key":"e_1_3_2_33_2","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1093\/infdis\/166.4.904","volume":"166","year":"1992","unstructured":"Tatarowicz, W. A., N. S. Lurain, and K. D. Thompson. 1992. A ganciclovir-resistant clinical isolate of human cytomegalovirus exhibiting cross-resistance to other DNA polymerase inhibitors. J. Infect. Dis.166:904-907.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_34_2","first-page":"A70.","volume":"37","year":"1998","unstructured":"Tatti, K. M., H. Stang, D. Barnard, D. Smee, and R. F. Schinazi. 1998. Mutations occur in highly conserved domains of murine cytomegalovirus DNA polymerase in cidofovir- and lobucavir-resistant strains. Antivir. Res.37:A70.","journal-title":"Antivir. Res."},{"key":"e_1_3_2_35_2","first-page":"983","volume":"136","year":"2000","unstructured":"Toro, J. R., L. V. Wood, N. K. Patel, and M. L. Turner. 2000. Topical cidofovir: a novel treatment for recalcitrant molluscum contagiosum in children infected with human immunodeficiency virus 1. Arch. Dermatol.136:983-985.","journal-title":"Arch. Dermatol."},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(96)00100-1"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.46.5.1329-1335.2002","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.46.5.1329-1335.2002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,23]],"date-time":"2023-04-23T12:01:22Z","timestamp":1682251282000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.46.5.1329-1335.2002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,5]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2002,5]]}},"alternative-id":["10.1128\/AAC.46.5.1329-1335.2002"],"URL":"https:\/\/doi.org\/10.1128\/aac.46.5.1329-1335.2002","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,5]]},"assertion":[{"value":"2001-08-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2001-12-28","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2002-05-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}